Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
14.30
-0.24 (-1.65%)
Aug 7, 2026, 4:00 PM EDT - Market closed
Immunic Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 186.63 | 15.48 | 35.67 | 46.67 | 106.75 | 86.86 |
Short-Term Investments | - | - | - | - | 9.63 | - |
Cash & Short-Term Investments | 186.63 | 15.48 | 35.67 | 46.67 | 116.37 | 86.86 |
Cash Growth | 1204.73% | -56.59% | -23.58% | -59.89% | 33.97% | -31.85% |
Other Current Assets | 2.13 | 7.39 | 3.66 | 5.86 | 9.49 | 18.13 |
Total Current Assets | 188.76 | 22.87 | 39.33 | 52.53 | 125.86 | 104.99 |
Net Property, Plant & Equipment | 0.98 | 1.18 | 1.54 | 1.77 | 1.85 | 1.1 |
Goodwill | - | - | - | - | - | 32.97 |
Other Long-Term Assets | - | - | - | - | 0.04 | 0.04 |
Total Assets | 189.74 | 24.05 | 40.87 | 54.3 | 127.75 | 139.1 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 11.01 | 10.14 | 7.85 | 5.1 | 4.28 | 3.75 |
Accrued Expenses | 22.43 | 18.65 | 12.91 | 18.66 | 7.99 | 7.07 |
Other Current Liabilities | 4.92 | 1.84 | 1.42 | 0.97 | 0.81 | 0.59 |
Total Current Liabilities | 38.36 | 30.62 | 22.18 | 24.73 | 13.08 | 11.4 |
Long-Term Leases | 0.15 | 0.11 | 0.26 | 0.64 | 0.99 | 0.58 |
Total Long-Term Liabilities | 0.15 | 0.11 | 0.26 | 0.64 | 0.99 | 0.58 |
Total Liabilities | 38.51 | 30.73 | 22.44 | 25.37 | 14.07 | 11.99 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Preferred Stock | - | - | 0.01 | - | - | - |
Common Stock | 0.01 | - | 0.01 | 0 | 0 | 0 |
Additional Paid-in Capital | 789.32 | 599.24 | 525.61 | 436.06 | 427.93 | 324.24 |
Accumulated Other Comprehensive Income | 3.06 | 2.65 | 4.21 | 3.76 | 3.04 | -0.25 |
Retained Earnings | -641.16 | -608.57 | -511.4 | -410.89 | -317.28 | -196.87 |
Shareholders' Equity | 151.23 | -6.68 | 18.44 | 28.93 | 113.68 | 127.12 |
Total Liabilities & Equity | 189.74 | 24.05 | 40.87 | 54.3 | 127.75 | 139.1 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.15 | 0.11 | 0.26 | 0.64 | 0.99 | 0.58 |
Net Cash (Debt) | 186.48 | 15.38 | 35.4 | 46.04 | 115.38 | 86.28 |
Net Cash Growth | 1223.14% | -56.57% | -23.09% | -60.10% | 33.73% | -31.94% |
Net Cash Per Share | 9.08 | 0.99 | 3.53 | 10.39 | 36.26 | 36.48 |
Book Value | 151.23 | -6.68 | 18.44 | 28.93 | 113.68 | 127.12 |
Book Value Per Share | 7.36 | -0.43 | 1.84 | 6.53 | 35.73 | 53.74 |
Tangible Book Value | 151.23 | -6.68 | 18.44 | 28.93 | 113.68 | 94.15 |
Tangible Book Value Per Share | 7.36 | -0.43 | 1.84 | 6.53 | 35.73 | 39.80 |